An Alzheimer's disease-derived biomarker signature identifies Parkinson's disease patients with dementia

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Berlyand, Yosef ^a   Weintraub, Daniel ^a   Xie, Sharon X ^a   Mellis, Ian A ^a   Doshi, Jimit ^b   Rick, Jacqueline ^a   McBride, Jennifer ^a   Davatzikos, Christos ^b   Shaw, Leslie M ^a   Hurtig, Howard ^a   Trojanowski, John Q ^a   Chen Plotkin, Alice S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; PEPTIDE FRAGMENT;

ACCURACY; ADULT; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL CAPACITY; PARKINSON DISEASE; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; AGED; CEREBROSPINAL FLUID; CLUSTER ANALYSIS; COMPLICATION; DEMENTIA; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; STATISTICAL MODEL;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; BIOMARKERS; CLUSTER ANALYSIS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DEMENTIA; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; TAU PROTEINS;

EID: 84958212059     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0147319     Document Type: Article

References (68)

1. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545-555. PMID: 15734686
2. Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology. 2010;34:143-151. doi: 10.1159/000275491 PMID: 20090375
3. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114(Pt 5):2283-2301. PMID: 1933245
4. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain. 2007;130:1787-1798. PMID: 17535834
5. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. 2008;23:837-844.
6. Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70:1017-1022. doi: 10.1212/01.wnl. 0000306632.43729.24 PMID: 18362281
7. Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang M, Cote LJ, et al. A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender. Arch Neurol. 1992;49:492-497. PMID: 1580811
8. Rosenthal E, Brennan L, Xie S, Hurtig H, Milber J, Weintraub D, et al. Association between cognition and function in patients with Parkinson disease with and without dementia. 2010;25:1170-1176.
9. Pressley JC, Louis ED, Tang MX, Cote L, Cohen PD, Glied S, et al. The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology. 2003;60:87-93. PMID: 12525724
10. Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, et al. The parkinson progression marker initiative (PPMI). Prog Neurobiol. 2011;95:629-635. doi: 10.1016/j.pneurobio.2011.09.005 PMID: 21930184
11. Marek K, Jennings D, Tamagnan G, Seibyl J. Biomarkers for Parkison's disease: tools to assess Parkinson's disease onset and progression. Ann Neurol. 2008;64:S111-S121. doi: 10.1002/ana.21602 PMID: 19127587
12. Sherer TB. Biomarkers for Parkinson's disease. Sci Transl Med. 2011;3:79ps14. doi: 10.1126/scitranslmed.3002488 PMID: 21508309
13. Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, et al. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. 2011;26:1428-1435.
14. Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5:463-466. doi: 10.1097/COH. 0b013e32833ed177 PMID: 20978388
15. Marder K, Tang M, Cote L, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol. 1995;52:695-701. PMID: 7619026
16. Uc EY, McDermott MP, Marder KS, Anderson SW, Litvan I, Como PG, et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology. 2009;73:1469-1477. doi: 10.1212/WNL.0b013e3181bf992f PMID: 19884574
17. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology. 2000;54:1596-1602. PMID: 10762499
18. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology. 2001;56:730-736. PMID: 11274306
19. Morley JF, Xie SX, Hurtig HI, Stern MB, Colcher A, Horn S, et al. Genetic influences on cognitive decline in Parkinson's disease. 2012;27:512-518.
20. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132:2958-2969. doi: 10.1093/brain/awp245 PMID: 19812213
21. Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain. 2009;132:1783-1794. doi: 10.1093/brain/awp044 PMID: 19286695
22. Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology. 2010;75:1055-1061. doi: 10.1212/WNL. 0b013e3181f39a78 PMID: 20720189
23. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403-413. doi: 10.1002/ana.21610 PMID: 19296504
24. Pellecchia MT, Santangelo G, Picillo M, Pivonello R, Longo K, Pivonello C, et al. Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. J Neurol. 2013;260:438-444. doi: 10.1007/s00415-012-6648-6 PMID: 22911513
25. Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol. 2011;69:655-663. doi: 10.1002/ana.22271 PMID: 21520231
26. Mollenhauer B, Rochester L, Chen-Plotkin A, Brooks D. What can biomarkers tell us about cognition in Parkinson's disease?. 2014;29:622-633.
27. Davatzikos C, Xu F, An Y, Fan Y, Resnick SM. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain. 2009;132:2026-2035. doi: 10.1093/brain/awp091 PMID: 19416949
28. Weintraub D, Dietz N, Duda JE, Wolk DA, Doshi J, Xie SX, et al. Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain. 2012;135:170-180. doi: 10.1093/brain/awr277 PMID: 22108576
29. Chen-Plotkin AS. Unbiased Approaches to Biomarker Discovery in Neurodegenerative Diseases. Neuron. 2014;84:594-607. doi: 10.1016/j.neuron. 2014.10.031 PMID: 25442938
30. Mattila P, Rinne J, Helenius H, Dickson D, Röyttä M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol. 2000;100:285-290. PMID: 10965798
31. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. 1993;50:140-148. PMID: 8431132
32. Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Vedders L, Peterson LK, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord. 2009;23:295-297. doi: 10.1097/WAD.0b013e31819c5ef4 PMID: 19812474
33. Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol. 2012;72:587-598. doi: 10.1002/ana.23659 PMID: 23037886
34. Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol. 2008;115:427-436. doi: 10.1007/s00401-008-0347-5 PMID: 18273624
35. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51:745-752. PMID: 2841426
36. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, et al. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement. 2015;11:e1-e120.
37. Mollenhauer B, Rochester L, Chen-Plotkin A, Brooks D. What can biomarkers tell us about cognition in Parkinson's disease?. 2014;29:622-633.
38. Lucas JA, Ivnik RJ, Smith GE, Bohac DL, Tangalos EG, Kokmen E, et al. Normative data for the Mattis dementia rating scale. 1998;20:536-547.
39. Weintraub D, Oehlberg KA, Katz IR, Stern MB. Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. 2006;14:169-175.
40. Fahn S, Elton R. Unified rating scale for Parkinson's disease. 1987:153-163.
41. Shapiro AM, Benedict RH, Schretlen D, Brandt J. Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol. 1999;13:348-358. PMID: 10726605
42. Brandt J BR. The Hopkins Verbal Learning Test-Revised. Psychological Assessment Resources. 2001.
43. Weintraub D, Moberg PJ, Culbertson WC, Duda JE, Stern MB. Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn Behav Neurol. 2004;17:195-200. PMID: 15622014
44. Chahine LM, Qiang J, Ashbridge E, Minger J, Yearout D, Horn S, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. 2013;70:852-858.
45. Hoehn M. Yahr. 1967:V7.
46. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990;40:1529-1534. PMID: 2215943
47. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, et al. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology. 2012;79:1944-1950. doi: 10.1212/WNL.0b013e3182735e9a PMID: 23035075
48. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid (1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005;51:336-345. PMID: 15563479
49. Su Y, Yajima M, Gelman AE, Hill J. Multiple imputation with diagnostics (mi) in R: Opening windows into the black box. 2011;45:1-31.
50. Irwin DJ, Lee VM, Trojanowski JQ. Parkinson's disease dementia: convergence of [alpha]-synuclein, tau and amyloid-[beta] pathologies. 2013;14:626-636.
51. Mollenhauer B, Trenkwalder C, von Ahsen N, Bibl M, Steinacker P, Brechlin P, et al. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord. 2006;22:200-208. PMID: 16899997
52. Braak H, Del Tredici K, Rüb U, de Vos RA, Steur ENJ, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197-211. PMID: 12498954
53. Braak H, Müller C, Rüb U, Ackermann H, Bratzke H, De Vos R, et al. Pathology associated with sporadic Parkinson's disease-where does it end? In: Anonymous Parkinson's Disease and Related Disorders.: Springer; 2006. pp. 89-97.
54. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. Striatal beta-amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol. 2008;67:155-161. doi: 10.1097/NEN. 0b013e31816362aa PMID: 18219254
55. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, et al. Lewy- and Alzheimertype pathologies in Parkinson's disease dementia: which is more important? Brain. 2011;134:1493-1505. doi: 10.1093/brain/awr031 PMID: 21596773
56. Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol. 2008;116:1-16. doi: 10.1007/s00401-008-0406-y PMID: 18592254
57. Jellinger K, Seppi K, Wenning G, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm. 2002;109:329-339. PMID: 11956955
58. Kramer JH, Levin BE, Brandt J, Delis DC. Differentiation of Alzheimer's, Huntington's, and Parkinson's disease patients on the basis of verbal learning characteristics. Neuropsychology. 1989;3:111-120.
59. Pillon B, Deweer B, Agid Y, Dubois B. Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch Neurol. 1993;50:374-379. PMID: 8460958
60. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30:7281-7289. doi: 10.1523/JNEUROSCI.0490-10.2010 PMID: 20505094
61. Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, Lee VM, et al. Concurrence of α-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol. 2002;104:7-11. PMID: 12070658
62. Lee VM, Giasson BI, Trojanowski JQ. More than just two peas in a pod: common amyloidogenic properties of tau and α-synuclein in neurodegenerative diseases. Trends Neurosci. 2004;27:129-134. PMID: 15036877
63. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. 2003;300:636-640. PMID: 12714745
64. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:311-321. doi: 10.1056/NEJMoa1312889 PMID: 24450890
65. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:322-333. doi: 10.1056/NEJMoa1304839 PMID: 24450891
66. AstraZeneca. An Efficacy and Safety Study of AZD3293 in Early Alzheimer's Disease (AMARANTH).
67. Eli Lilly and Company. Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4).
68. Eisai Inc. Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild Dementia Due to Alzheimer's Disease.